Cargando…

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?

Currently, one of the leading treatments for non-small-cell lung cancer is immunotherapy involving immune checkpoint inhibitors. These monoclonal antibodies restore the anti-tumour immune response altered by negative immune checkpoint interactions. The most commonly used immunotherapeutics in monoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krzyżanowska, Natalia, Wojas-Krawczyk, Kamila, Milanowski, Janusz, Krawczyk, Paweł
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950480/ https://www.ncbi.nlm.nih.gov/pubmed/35328510 http://dx.doi.org/10.3390/ijms23063087

Ejemplares similares

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

Double Guard Efficiency and Safety—Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune Checkpoints in Non-Small Cell Lung Cancer Patients
por: Kalinka, Ewa, et al.
Publicado: (2023)

The influence of different culture microenvironments on the generation of dendritic cells from non-small-cell lung cancer patients
por: Krawczyk, Paweł, et al.
Publicado: (2007)

Clinical Application Perspectives of Lung Cancers 3D Tumor Microenvironment Models for In Vitro Cultures
por: Wieleba, Irena, et al.
Publicado: (2022)

Tumor Microenvironment—A Short Review of Cellular and Interaction Diversity
por: Bożyk, Aleksandra, et al.
Publicado: (2022)

Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer
por: Krawczyk, Paweł, et al.
Publicado: (2012)

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
por: Nicoś, Marcin, et al.
Publicado: (2020)

Failure of Immunotherapy—The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer
por: Błach, Justyna, et al.
Publicado: (2021)

In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation
por: Wieleba, Irena, et al.
Publicado: (2022)

Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience
por: Chmielewska, Izabela, et al.
Publicado: (2023)

Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

The Application of Real-Time PCR Technique to Detect Rare Cell Clones with Primary T790M Substitution of EGFR Gene in Metastases of Non-small Cell Lung Cancer to Central Nervous System in Chemotherapy Naive Patients
por: Powrózek, Tomasz, et al.
Publicado: (2014)

HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery
por: Grenda, Anna, et al.
Publicado: (2020)

Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2016)

Aptamers in Non-Small Cell Lung Cancer Treatment
por: Wieleba, Irena, et al.
Publicado: (2020)

Molecular and Clinical Premises for the Combination Therapy Consisting of Radiochemotherapy and Immunotherapy in Non-Small Cell Lung Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2021)

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2022)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

Imperfect Predictors for Lung Cancer Immunotherapy—A Field for Further Research
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2020)

Viral Infection and Lung Cancer Immunotherapy
por: Kalinka, Ewa, et al.
Publicado: (2021)

Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients
por: Frąk, Małgorzata, et al.
Publicado: (2022)

The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2013)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
por: Szczyrek, Michał, et al.
Publicado: (2021)

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
por: Krawczyk, Paweł, et al.
Publicado: (2013)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report
por: Kamila, Wojas-Krawczyk, et al.
Publicado: (2013)

Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique
por: Nicoś, M., et al.
Publicado: (2017)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer
por: Nicoś, Marcin, et al.
Publicado: (2017)

New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary
por: Krawczyk, Paweł, et al.
Publicado: (2022)

Septin 9 promoter region methylation in free circulating DNA—potential role in noninvasive diagnosis of lung cancer: preliminary report
por: Powrózek, Tomasz, et al.
Publicado: (2014)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
por: Terlecka, Paulina, et al.
Publicado: (2021)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer
por: Nicoś, Marcin, et al.
Publicado: (2015)

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2021)

Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
por: Grenda, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_elj2p5aeb1d0buqktcb79si5hd